DNA-encoded library is a collection of compounds conjugated to unique DNA strand which serves as an amplifiable identification barcode for that particular compound. DEL (DNA-enabled library) is a technology for synthesis and screening on the unprecedented scale of collections of small molecule compounds and is used to bridge the fields of combinatorial chemistry and molecular biology for new drug developments. The use of DNA-encoded library is very popular in identifying bioactive chemical compounds and is a rapidly growing drug discovery platform in the post-genome era. The advantage of DNA-encoded library technology over traditional high-throughput screening (HTS) approaches, DEL screening allows a huge number of compounds to be interrogated simultaneously. This makes DNA-encoded library technology mature and prominent approach to early-stage drug discovery.
Advantages of DNA-encoded library over high-throughput screening and growing investments in research and developments through merger & collaborations can be attributed to the growth of DNA-encoded library market in the coming years. In December 2019, Amgen acquired Nuevolution for US $167 Million to advance its drug discovery efforts.
Major Key Players of the DNA-encoded Library Market are:
Amgen Inc., Novartis AG, Merck KGaA, GlaxoSmithKline plc, HitGen Inc. and X-CHEM among others.
Amgen Inc., Novartis AG, Merck KGaA, GlaxoSmithKline plc, HitGen Inc. and X-CHEM among others.
No comments:
Post a Comment